CCN2 and Hepatic fibrosis: Tamaki et al (33) demonstrated that telmisartan (an AGTR1 receptor blocker) inhibited hepatic fibrosis, induced downregulation of tumour necrosis factor-α, TGF-β1, and CTGF mRNA expression, and reduced the number of α-smooth muscle actin-positive cells in the liver.